Hope After Checkpoint Failure
(Chicago, Illinois) March 4, 2026
ExoMira Medicine Inc. (“ExoMira”) announced the publication of a landmark peer-reviewed study in The Journal of Clinical Investigation (Liu, Iyer, Li, et al.), led by ExoMira co-founders Dr. Deyu Fang and Dr. Huiping Liu. The study identifies a second, independent mechanism by which the deubiquitinase USP22 enables tumors to evade immune destruction - expanding the scientific foundation for ExoMira’s USP22 inhibitor program, including its lead candidate MIRA-1.
Background: why antigen presentation matters in immunotherapy
Immune checkpoint blockade (ICB) therapies such as anti–PD-1/PD-L1 can deliver durable responses for some patients, but the majority of solid tumors do not respond - or develop resistance. A well-established reason is failure of antigen presentation: if tumor neoantigens are not displayed on MHC class I (MHC-I), cytotoxic CD8⁺ T cells cannot reliably recognize and kill cancer cells, even when checkpoint pathways are inhibited. Clinically, reduced or lost MHC-I expression is frequently observed in solid tumors and is strongly linked to “cold” tumor immune microenvironments and poor ICB outcomes.
Core finding: USP22 drives “MHC-I darkening” and blocks CD8⁺ T-cell recognition
This JCI study demonstrates that, beyond previously described immune-suppressive effects (including strengthening Treg function), tumors can use USP22 to directly suppress MHC-I–mediated neoantigen presentation—effectively “darkening” tumors to CD8⁺ T cells.
Mechanistic pathway identified:
USP22 → EZH2 stabilization → epigenetic silencing of MHC-I genes
The authors show USP22 functions as a deubiquitinase that stabilizes the methyltransferase EZH2, promoting transcriptional silencing of key MHC-I components (including β2M). Importantly, “rescue” experiments support causality: reconstituting EZH2 blunts the immune-activating benefits of USP22 inhibition, indicating the USP22–EZH2 axis is a functional driver of antigen-presentation loss—not merely a correlation.
Therapeutic relevance: USP22 inhibition reverses resistance to anti–PD-1 in preclinical models
Across genetic and pharmacologic approaches, USP22 inhibition increased tumor immunogenicity, restored MHC-I expression, and enhanced CD8⁺ T-cell activation and killing. In multiple preclinical contexts (including lung cancer and triple-negative breast cancer models described by the authors), USP22 inhibition sensitized tumors to anti–PD-1 therapy and overcame anti–PD-1 resistance—supporting a rationale for combination regimens (USP22 inhibitor + checkpoint blockade) aimed at converting non-responders into responders.
Translational relevance: USP22 as a biomarker for checkpoint response risk
In analyses of human tumor samples, USP22 expression inversely tracked with β2M (a key MHC-I component) and with intratumoral CD8⁺ T-cell infiltration across solid tumor settings. In lung cancer biopsies from patients treated with anti–PD-1 therapy, higher pretreatment USP22 expression was associated with poorer responsiveness—supporting the potential of USP22 as a practical biomarker to identify patients at higher risk of checkpoint resistance, and to guide rational combination strategies.
Strategic significance for ExoMira
Collectively, these findings reframe USP22 as a dual-benefit immuno-oncology target:
Immune-boosting by restoring antigen presentation and CD8⁺ T-cell activity through reversal of MHC-I suppression, and
Oncotargeting potential through disruption of USP22-dependent tumor programs described across multiple cancer contexts.
ExoMira’s lead program, MIRA-1, is being developed as a first-in-class USP22 inhibitor-based immunotherapy with a broad pancancer target profile and a mechanistically grounded combination opportunity with checkpoint blockade.